

Drug Resistance Mutations in HIV-1

Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, Brian Conway, MD, Richard T. D'Aquila, MD, Lisa M. Demeter, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. Schapiro, MD, Amalio Telenti, MD, PhD, and Douglas D. Richman, MD

The International AIDS Society–USA (IAS–USA) Drug Resistance Mutations Group is a volunteer panel of experts that meets regularly to review and interpret new data on HIV-1 resistance. The focus of the group is to identify mutations associated with clinical resistance to HIV-1. These mutations have been identified by 1 or more of the following criteria: (1) *in vitro* passage experiments or validation of contribution to resistance by using site-directed mutagenesis; (2) susceptibility testing of laboratory or clinical isolates; (3) genetic sequencing of viruses from patients in whom the drug is failing; (4) correlation studies between genotype at baseline and virologic response in patients exposed to the drug. Drugs that have been approved by the US Food and Drug Administration (FDA) or are available through expanded access protocols are included.

The IAS–USA Drug Resistance Mutations Figures are designed for use in identifying mutations associated with drug resistance and in making therapeutic decisions. Care should be taken when using this list of mutations for surveillance or epidemiologic studies of transmission of drug-resistant virus; a number of amino acid substitutions, particularly minor mutations, represent polymorphisms, which in isolation may not reflect prior drug selective pressure or reduced drug susceptibility.

In the context of making clinical decisions regarding antiretroviral therapy, evaluating the results of HIV genotypic testing includes: (1) assessing whether the pattern or absence of a pattern in the mutations is consistent with the patient's antiretroviral regimen; (2) recognizing that in the absence of drug (selection

pressure), resistant strains may be present at levels below the limit of detection of the test; analyzing stored samples (collected under selection pressure) could be useful in this setting; and (3) recognizing that virologic failure of the first regimen typically involves HIV-1 isolates with resistance to only 1 or 2 of the drugs in the regimen; in this setting, resistance most commonly develops to lamivudine or the nonnucleoside reverse transcriptase inhibitors.¹⁻⁵ This paradox may involve patient nonadherence, laboratory error, drug-drug interactions leading to subtherapeutic drug levels, and possibly compartmental issues, indicating that drugs may not reach optimal levels in specific cellular or tissue reservoirs.

Revised recommendations for antiretroviral resistance testing were recently published by the IAS–USA HIV Resistance Testing Guidelines Panel⁶ and can be found on the IAS–USA Web site at www.iasusa.org.

Revisions to the Figures in this October 2003 Update

In the nucleoside and nucleotide reverse transcriptase inhibitor (nRTI) category, mutations for emtricitabine have been added. Emtricitabine and lamivudine share a similar reverse transcriptase M184V/I mutation pattern (see User Note 10).⁷ In addition, the K65R mutation has been added to stavudine, lamivudine, and emtricitabine. Data presented at recent conferences indicate that this mutation can confer resistance to stavudine and cross-resistance to lamivudine and emtricitabine.⁸⁻¹² In the protease inhibitor (PI) category, the

V32I and the I84A/C have been added to the list of accumulated mutations conferring multi-PI resistance (see User Note 9).¹³⁻¹⁸ In addition, mutations have been added for tipranavir/ritonavir, which is currently available through an expanded access protocol and is not approved for use by the US FDA. A number of major (L33I/F/V, V82L/T, I84V, and L90M) and minor (L10I/V, K20M/L/T, M46I, and I54V) mutations were identified for tipranavir/ritonavir from data presented at the XII International HIV Drug Resistance Workshop in Los Cabos, Mexico.^{19,20} Based on data published by Colonna and colleagues,²¹ 7 minor mutations associated with resistance to atazanavir (L10I/F/V, K20R/M/I, L24I, L33I/F/V, M36I/L/V, G48V, and G73C/S/T/A) have been added. For lopinavir/ritonavir, the I54V/L mutation has been expanded to I54V/L/A/M/T/S²²⁻²⁴ and the I47V mutation has been expanded to I47V/A.^{15,25} In the fusion inhibitor category, the discussion in User Note 25 has been expanded to include current findings on issues that affect susceptibility to enfuvirtide.²⁶⁻²⁸

The group is currently summarizing the HIV-1 resistance mutations that are associated with non-subtype B virus and plans to include it in the next update. Data continues on HIV susceptibility to antiretroviral drugs. (cont'd, pg 220)

The IAS–USA Mutations Figures are available on a pocket-sized folding card. Copies of the card can be ordered by phone at (415) 544-9400, at www.iasusa.org/resistance_mutations/index.html, by mail, or by e-mail at: resistance@iasusa.org.

Author Affiliations: Dr Johnson (Group Chair), Veterans Affairs Medical Center, Birmingham, and the University of Alabama at Birmingham School of Medicine, Birmingham, AL; Dr Brun-Vézinet, Hôpital Bichat-Claude Bernard, Paris, France; Dr Clotet, Fundacio irsiCAIXA and HIV Unit, Hospital Universitari Germans Trias I Pujol, Barcelona, Spain; Dr Conway, University of British Columbia, Vancouver, BC; Dr D'Aquila, Vanderbilt University Medical Center, Nashville, Tenn; Dr Demeter, University of Rochester Medical Center, Rochester, NY; Dr Kuritzkes, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; Dr Pillay, Royal Free and University College Medical School, London, England; Dr Schapiro, Stanford University School of Medicine, Palo Alto, Calif; Dr Telenti, University Hospital of Lausanne, Switzerland; Dr Richman (Group Vice Chair), Veterans Affairs San Diego Healthcare System, and the University of California San Diego, La Jolla, Calif.

MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE ASSOCIATED WITH RESISTANCE TO REVERSE TRANSCRIPTASE INHIBITORS

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors

Multi-nRTI Resistance: 151 Complex	A	V	F	F	Q					
	62	75	77	116	151					
	V	I	L	Y	M					
Multi-nRTI Resistance: 69 Insertion Complex ¹	M	A	D	▼	K			L	I	K
	41	62	67	69	70			210	215	219
	L	V	N	insert	R			W	Y	Q
								F	F	F
Multi-nRTI Resistance: NAMs ²	M	L	D	K		V		L	I	K
	41	44	67	70		118		210	215	219
	L	D	N	R		I		W	Y	Q
								F	F	F
Zidovudine ^{3,4}	M	E	D	K		V		L	T	K
	41	44	67	70		118		210	215	219
	L	D	N	R		I		W	Y	Q
								F	F	F
Stavudine ³⁻⁵	M	E	K	D	K		V	L	T	K
	41	44	65	67	70		118	210	215	219
	L	D	R	N	R		I	W	Y	Q
								F	F	F
Didanosine ^{6,7}			K		L					
			65		74					
			R		V					
Zalcitabine			K	F	L					M
			65	69	74					184
			R	D	V					V
Abacavir ⁸			K		L		Y			M
			65		74		115			184
			R		V		F			V
Lamivudine ^{9,10}	E	K					V			M
	44	65					118			184
	D	R					I			V
										I
Emtricitabine ¹⁰			K							M
			65							184
			R							V
										I
Tenofovir ^{3,11}			K							
			65							
			R							

Nonnucleoside Reverse Transcriptase Inhibitors

Multi-NNRTI Resistance ^{12,13}			K	V				Y		
			103	106				188		
			N	M				L		
Multi-NNRTI Resistance: Accumulation of Mutations ¹⁴		L	V				Y	G		M
		100	106				181	190		230
		I	A				C	S		-
							I	A		
Nevirapine		L	K	V	V		Y	Y	C	
		100	103	106	108		181	188	190	
		I	N	A	I		C	C	A	
				M			I	L	H	
Delavirdine ¹⁵			K	V			Y	Y		P
		103	106				181	188		236
		N	M				C	L		L
Efavirenz ¹⁵⁻¹⁷		L	K	V	V		Y	Y	G	P
		100	103	106	108		181	188	190	225
		I	N	M	I		C	L	S	H
							I	A		


Date of Revision: October 2003

MUTATIONS IN THE PROTEASE GENE ASSOCIATED WITH RESISTANCE TO PROTEASE INHIBITORS

Protease Inhibitors¹⁸

Protease Inhibitor	10	20	21	32	33	36	46	47	50	53	54	63	71	73	77	82	84	88	90	
Multi-PI Resistance: Accumulation of Mutations ¹⁹	L F I R V			V I		M L	M L		I V L				V M L			V A F I S	I V A C		L M	
Indinavir ²⁰	L F I R V	K M R	L I	V I		L I	M L	M L			I V		Λ V T	G S A	V I	V A F T	I V		L M	
Ritonavir	L F I R V	K M R	L I	V I	L F	M I	M L	M L			I V		Λ V T		V I	V A F T S	I V		L M	
Saquinavir	L F I R V												G V	I V	A S	C I	V A	V V	I V	L M
Nelfinavir	L F I			D N		M I	M L	M L					A V I		V I	V A F T S	I V	N J S	L M	
Amprenavir	L F I R V			V I		M L	M L	I V	I V				C S				I V		L M	
Lopinavir/ Ritonavir ^{21,22}	L F I R V	K M R	L I	V I	L F	M I	M L	I V	I V	F L	I V	L P	A V T	C S		V A F I S	I V		L M	
Atazanavir ²³	L F I R V	K M R	L I	V I	L F	M I	M L	G V	I V				Λ V	C C S T A		V Λ	I V	N S	L M	
Tipranavir/ Ritonavir ²⁴ (expanded access)	L F I R V	K M R				L I	M L									V A F I S	I V		L M	

MUTATIONS IN THE GP41 ENVELOPE GENE ASSOCIATED WITH RESISTANCE TO ENTRY INHIBITORS



User Notes October 2003.

The IAS–USA Drug Resistance Mutations Group reviews new data on HIV drug resistance in order to maintain a current list of mutations associated with clinical resistance to HIV. This list includes mutations that may contribute to a reduced virologic response to a drug. These mutations have been identified by 1 or more of the following criteria: (1) in vitro passage experiments or validation of contribution to resistance by using site-directed mutagenesis; (2) susceptibility testing of laboratory or clinical isolates; (3) genetic sequencing of viruses from patients in whom the drug is failing; (4) correlation studies between genotype at baseline and virologic response in patients exposed to the drug. Drugs that have been approved by the US Food and Drug Administration (FDA) or are available through expanded access protocols are included. Additional information on the mutations is provided, where necessary, in these user notes.

1. The 69 insertion complex, consisting of a mutation at codon 69 (typically T69S) and followed by an insertion of 2 or more amino acids (S-S, S-A, S-G, or others), is associated with resistance to all FDA-approved nRTIs. The 69 insertion complex is often accompanied by mutations at other sites. Some other amino acid changes from the wild-type T in codon 69 without the insertion may also be associated with broad nRTI resistance.

2. The nRTI-associated mutations (NAMs), including M41L, E44D, D67N, K70R, V118I, L210W, T215Y/F, and K219Q/E, are associated with cross-resistance to nRTIs and are represented by vertical pink lines. Zidovudine and stavudine select for these mutations, and as such, the positions and mutations are indicated on the bars along with the pink lines. For other nRTIs, the NAMs are not commonly selected by those drugs, but the presence of the NAMs confers cross-resistance to the drugs. This is represented by pink lines only at the positions.

The E44D and V118I mutations are listed as NAMs. In a recent study, the E44D and V118I mutations were more common in virus from patients who had been on zidovudine and lamivudine, and were associated with higher-level resistance to zidovudine (Stoekli et al, *Antimicrob Agents Chemother*, 2002). When present together with other NAMs, the E44D and V118I mutations confer resistance to lamivudine. Analysis from the AIDS Clinical Trials Group (ACTG) study 136 has shown that the V118I mutation is commonly selected by a zidovudine/didanosine regimen (Shafer et al, *J Infect Dis*, 1995). Findings from ACTG study

241 have shown that the E44D mutation is commonly selected by zidovudine/didanosine (Hanna et al, *J Infect Dis*, 2002) and that the E44D mutation is associated with a significantly worse response to treatment with zidovudine and didanosine, with or without nevirapine (Precious et al, *AIDS*, 2000). The significance of E44D or V118I when each occurs in isolation is unknown (Romano et al, *J Infect Dis*, 2002; Walter et al, *Antimicrob Agents Chemother*, 2002; Girouard et al, *Antivir Ther*, 2002).

3. The M184V mutation may enhance susceptibility to zidovudine, stavudine, or tenofovir. This effect may be overcome by an accumulation of NAMs or other mutations. The clinical significance of this effect is not known.

4. Data on revertant mutations in codon 215 indicate that the T215D/C/S/E/N/A/V substitutions confer increased risk of virologic failure of zidovudine and stavudine in antiretroviral-naïve adults starting therapy with these drugs (Riva et al, *Antivir Ther*, 2002). In vitro studies and preliminary clinical studies suggest that the T215Y mutant may emerge quickly from these mutations in the presence of zidovudine or stavudine (Garcia-Lerma et al, *Proc Natl Acad Sci U S A*, 2001; Lanier et al, *Antivir Ther*, 2002; Riva et al, *Antivir Ther*, 2002).

5. Mutations at codon 75 (V75T/M/S/A) have been observed in vitro and may confer a low-level change in susceptibility to stavudine (Lacey et al, *Antimicrob Agents Chemother*, 1994).

6. The K65R mutation or the L74V mutation, alone or in combination with the NAMs or T69D/N can lead to didanosine resistance.

7. Based on preliminary, yet-unpublished data, the M184V mutation does not appear to have a negative impact on in vivo responses to didanosine, even though the mutation reduces susceptibility in vitro (Winters et al, *Antivir Ther*, 2002; Eron et al, *Antivir Ther*, 2002; Pozniak et al, *Antivir Ther*, 2002).

8. When present with NAMs, the M184V mutation contributes to reduced susceptibility to abacavir and is associated with impaired response in vivo. However, when present alone, the M184V mutation does not appear to be associated with a reduced virologic response to abacavir in vivo (Harrigan et al, *J Infect Dis*, 2000).

9. The E44D and V118I mutations were reported to confer low-level resistance to

lamivudine when accompanied by several other nRTI-associated mutations (M41L, D67N, L210W, T215Y/F, K219Q/E) in the absence of a concurrent M184V mutation (Hertogs et al, *Antimicrob Agents Chemother*, 2000). Data presented but not yet published (D'Arminio-Monforte et al, 8th CROI, 2001), reported no association over the short term between E44D or V118I and virologic response to a lamivudine-containing combination regimen. (See also User Note 2.)

10. Emtricitabine and lamivudine have similar reverse transcriptase M184V/I patterns (Quinn et al, *ICAAC*, 2003). In addition, the K65R mutation can confer cross-resistance to emtricitabine and lamivudine (Miller et al, *ICAAC*, 2003; Miller et al, *Antivir Ther*, 2003; Miller et al, 10th CROI, 2003; Parikh et al, *Antivir Ther*, 2003; Ruane et al, *Antivir Ther*, 2003; McArthur et al, *Antivir Ther*, 2003). Additional mutations that confer resistance or cross-resistance to emtricitabine are possible, but are yet to be described.

11. The accumulation of NAMs (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E [note: data here do not include E44D and V118I]) increases resistance to tenofovir. Mutations M41L and L210W contribute more than others. Therefore, the number and type of NAMs will determine the degree of reduced response. T69D/N/S may also contribute to a reduced response to tenofovir (Miller et al, *Antivir Ther*, 2002; Lu et al, *Antivir Ther*, 2002; Masquelier et al, *Antivir Ther*, 2002).

12. The K103N or Y188L mutation alone can substantially reduce the clinical utility of all currently approved NNRTIs.

13. The V106M mutation confers high-level resistance in vitro to nevirapine, delavirdine, and efavirenz (Brenner et al, *AIDS*, 2003). This mutation has been observed only in HIV clade C clinical isolates, although site-directed mutagenesis indicates that V106M confers cross-resistance to all NNRTIs in HIV clade B virus.

14. Accumulation of 2 or more of these mutations substantially reduces the clinical utility of all of the currently approved NNRTIs.

15. The prevalence of the Y318F mutation in clinical isolates along with mutations K103N, Y181C, or P236L was approximately 5%, 2%, and 15%, respectively (Kemp et al, *Antivir Ther*, 2001). In vitro this mutation confers resistance to nevirapine, delavirdine, and efavirenz.

16. The Y181C/I mutation is not selected by efavirenz, but its presence contributes to low-level cross-resistance to the drug. Clinical impact of this mutation may be overcome with a fully active antiretroviral combination regimen, although no clinical trial data yet address this question.

17. V108I and P225H each contribute to efavirenz resistance when present in combination with other NNRTI-associated mutations. Although V108I or P225H alone does not confer measurable resistance in laboratory strains of HIV-1, their presence in a clinical isolate may indicate prior selection for efavirenz-resistant variants.

18. Resistance mutations in the protease gene are classified as either "major" or "minor" (if known).

Major: In general, major mutations are either (1) selected first in the presence of the drug; or (2) shown at the biochemical or virologic level to lead to an alteration in drug binding or an inhibition of viral activity or viral replication. By themselves, major mutations have an effect on phenotype. In general, these mutations tend to be the major contact residues for drug binding.

Minor: In general, minor mutations appear later than major mutations, and by themselves do not have a significant effect on phenotype. In some cases, their effect may be to improve replicative fitness of virus carrying major mutations.

19. Accumulation of 4 or more of these mutations is likely to cause multi-PI resistance (Palmer et al, *AIDS*, 1999; Shafer et al, *Ann Intern Med*, 1998).

20. For indinavir, the mutations listed as major may not be the first mutations selected, but they are present in most clinical isolates in combination with other mutations.

21. Major and minor mutations have not been designated for lopinavir/ritonavir-associated resistance since currently there are no clear data defining degrees of influence with this drug combination. The accumulation of 6 or more of these mutations is associated with a diminished response to lopinavir/ritonavir. The product information states that accumulation of 7 or 8 mutations confers resistance to the drug. However, recent data suggest as few as 4 mutations can be associated with such high-level resistance (Prado et al, *AIDS*, 2002). Further clinical experience and research are needed to better define the mutations that affect the

clinical effectiveness of lopinavir/ritonavir. It is reasonable to consider phenotyping to assess this in individual cases.

22. Protease mutation L63P is common in viruses that have never been exposed to PIs (Kozal et al, *Nat Med*, 1996) and may be more prevalent in viruses from patients in whom a PI-containing regimen has failed. However, by itself, L63P does not cause any appreciable increase in the IC₅₀ for any PI. L63P is listed for lopinavir/ritonavir (and not any other PI) because studies have shown that this mutation, when present with multiple other mutations, is associated with clinical failure.

23. When administered to patients as the initial PI, atazanavir selects for the mutations I50L and A71V (Colonna et al, *Antivir Ther*, 2002). When used as a subsequent PI in combination with saquinavir, atazanavir selects for I54L and I84V (Colonna et al, *Antivir Ther*, 2002). In vitro, atazanavir selects for V32I, M46I, I84V, and N88S (Gong et al, *Antimicrob Agents Chemother*, 2000). Although other mutations, such as V82A and L90M, have not been selected for by atazanavir either in vitro or in vivo, these mutations have been shown to confer cross-resistance to atazanavir, particularly when present in combination with each other or with other known PI resistance mutations (Colonna et al, *Antivir Ther*, 2000).

24. Tipranavir/ritonavir is currently available through an expanded access protocol and is not approved by the FDA.

25. To date, resistance mutations in the gp41 envelope gene have been identified primarily at positions 36 to 45 of the first heptad repeat (HR1) region. These mutations have been identified in viruses from patients having been on enfuvirtide and have been shown to confer resistance or reduced susceptibility (Wei et al, *Antimicrob Agents Chemother*, 2002; Sista et al, *Antivir Ther*, 2002; Mink et al, *Antivir Ther*, 2002). It is important to note that wild-type viruses lacking any mutations in the depicted HR1 region vary 500-fold in susceptibility and such pretreatment susceptibility differences were not associated with differences in clinical response (Labrosse et al, *J Virol*, 2003; Greenberg et al, 10th CROI, 2003). Furthermore, it is possible that mutations and/or polymorphisms in other regions in the envelope, yet to be identified, as well as coreceptor usage and density may affect susceptibility to enfuvirtide (Reeves et al, *PNAS*, 2002). Further research is needed to define the full spectrum of clinically relevant muta-

tions conferring enfuvirtide resistance. Testing to detect only the depicted HR1 mutations may not be adequate for clinical management of suspected failure of regimens including enfuvirtide and must be interpreted in the context of resistance testing results for all other components of the regimen.

Key. For each amino acid residue, the letter above the bar indicates the amino acid associated with wild-type virus and the letter(s) below indicate the substitution(s) that confer viral resistance. The number shows the position of the mutation in the protein. Mutations selected by protease inhibitors in Gag cleavage sites are not listed because their contribution to resistance is not yet fully defined. HR1 indicates first heptad repeat; NAMs indicates nRTI-associated mutations; nRTI indicates nucleoside reverse transcriptase inhibitor; NNRTI indicates nonnucleoside reverse transcriptase inhibitor; PI indicates protease inhibitor. The figures were last published in *Topics in HIV Medicine* in May/June 2003.

Amino acid abbreviations: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.

The IAS–USA Drug Resistance Mutations Group

In June 2003, as part of a regular rotation of the members and roles of the group, Victoria A. Johnson, MD, was named Chair of the IAS–USA Drug Resistance Mutations Group. Deenan Pillay, MD, PhD, and Amalio Telenti, MD, PhD, were newly appointed to the group. Robert M. Grant, MD, MPH, from the Gladstone Institute of Virology and Immunology in San Francisco, Clive Loveday, MD, PhD, from the International Clinical Virology Centre in Buckinghamshire, England, and Robert W. Shafer, MD, from the Stanford University School of Medicine, have completed their terms on the project, and have rotated off. The group is grateful for their participation during the last few years.

The IAS–USA Drug Resistance Mutations Group was originally a subgroup of the IAS–USA HIV Resistance Testing Panel. In 2000, the Drug Resistance Mutation Group became an independent entity. The group has forged a collaborative process designed to identify key HIV-1 drug resistance mutations through independent and unbiased consensus, and seeks to rapidly deliver emerging information on resistance to clinical practitioners.

References

- Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-1 infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. *JAMA*. 2000;283: 205-211.
- Havir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. *JAMA*. 2000;283:229-234.
- Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. *AIDS*. 2000;14:1195-1201.
- Galleo O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. *AIDS*. 2001;15:1894-1896.
- Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med*. 2002;346:2039-2046.
- Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of the International AIDS Society–USA panel. *Clin Infect Dis*. 2003;37:113-128.
- Quinn JB, Borroto-Esoda K, Hinkle J, Shaw A, Harris J, Rousseau F. Overview of the genotypic findings from emtricitabine-treated HIV+ patients. [Abstract H-908.] 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003.
- Miller MD, Margot NA, McColl DJ, Coakley DF, Cheng AK. Characterization of virologic failure through 96 weeks among treatment-naïve patient taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). *Antivir Ther*. 2003;8: S553.
- Miller MD, White KL, Petropoulos CJ, Parkin NT. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations. [Abstract P616.] 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003; Boston, Mass.
- Parikh U, Koontz D, Hammond J, et al. K65R: a multi-nucleoside resistance mutation of low but increasing frequency. *Antivir Ther*. 2003;8:S152.
- Ruane P, Lubner A, Akil B, et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. *Antivir Ther*. 2003;8:S42.
- McArthur RD, Crane LR, Alvarez D, Fairfax M, Richmond D, Curtis G. Factors associated with selection of the K65R mutation: a retrospective chart review. *Antivir Ther*. 2003;8: S835.
- Shafer RW, Hsu P, Patick AK, Craig C, Brendel V. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. *J Virol*. 1999;73:6197-6202.
- Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. *Antimicrob Agents Chemother*. 2002;46:731-738.
- Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. *J Virol*. 1998;72:7532-7541.
- Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. *Antimicrob Agents Chemother*. 2000;44: 2319-2326.
- Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. *J Virol*. 2003;77:4836-4847.
- Mo H, Parkin N, Stewart KD, et al. I84A and I84C mutations in protease confer high-level resistance to protease inhibitors and impair replication capacity. *Antivir Ther*. 2003;8:S56.
- McCallister S, Kohlbrenner V, Squires K, et al. Characterization of the impact of genotype, phenotype, and inhibitory quotient on antiviral activity of tipranavir in highly treatment-experienced patients. *Antivir Ther*. 2003;8: S15.
- Hall D, McCallister S, Neubacher D, Kraft M, Mayers DL. Characterization of treatment-emergent resistance mutations in two Phase II studies of tipranavir. *Antivir Ther*. 2003;8:S16.
- Colonna RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. *Antimicrob Agents Chemother*. 2003;47: 1324-1333.
- Monno L, Saracino A, Scudeller L, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naïve subjects with prior protease inhibitor experience. *J Acquir Immune Defic Syndr*. 2003;33:439-447.
- Parkin NT, Chappay C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. *AIDS*. 2003;17: 955-961.
- Rice H, Nadler J, Schaenman J, et al. Genotypic predictors of response to lopinavir/ritonavir in clinical practice. *Antivir Ther*. 2003;8:S169.
- Kagan RM, Shenderovich M, Ramnarayan K, Heseltine PNR. Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. *Antivir Ther*. 2003;8:S54.
- Labrosse B, Labernardiere JL, Dam E, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. *J Virol*. 2003;77: 1610-1613.
- Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. [Abstract 141.] 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003; Boston, Mass.
- Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. *Proc Natl Acad Sci U S A*. 2002; 99:16249-16254.

Acknowledgements

The IAS–USA Drug Resistance Mutations Group thanks Jennifer Ham, MPH, for managing the efforts of the group, and Neil Parkin, PhD, of ViroLogic Inc. for responding to panel questions and providing information.

Comments?

The IAS–USA Drug Resistance Mutations Group welcomes comments on the mutations figures and user notes. Please send your evidence-based comments, including relevant reference citations, to the IAS–USA at resistance@iasusa.org or by fax at (415) 544-9401. Please include your name and institution.

Financial Disclosures: The authors disclose the following affiliations with commercial supporters that may have interests related to the content of this article:

Dr Brun-Vézinet has received grant support from bioMérieux, Bristol-Myers Squibb, GlaxoSmithKline, PE Biosystems, and Visible Genetics and has served as a consultant to GlaxoSmithKline and Visible Genetics; Dr Clotet has received grant

support from Bristol-Myers Squibb, Gilead, Roche, and Visible Genetics; Dr Conway has received research support from Boehringer Ingelheim and research funding from Abbott, Agouron, Bristol-Myers Squibb, Schering, and Triangle; Dr D'Aquila has served as a speaker or on a speakers bureau for Agouron, Bristol-Myers Squibb, Gilead, ViroLogic, and Visible Genetics and as a consultant to Bristol-Myers Squibb and GlaxoSmith-Kline; he also receives research grant support from Bristol-Myers Squibb; Dr Demeter has served on the speakers bureau and scientific advisory committee for Glaxo SmithKline and has received research support from Applied Biosystems, Bristol-Myers Squibb/DuPont Merck, and Visible Genetics; Dr Johnson has served as a consultant to GlaxoSmithKline and Bristol-Myers

Squibb and as a speaker or on a speakers bureau for Abbott, Boehringer Ingelheim/Roxanne, Bristol-Myers Squibb, Chiron, GlaxoSmithKline, Merck, Roche, Vertex, and ViroLogic; she has received grant support from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmith-Kline, and Visible Genetic; Dr Kuritzkes has served as a consultant to Abbott, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Ortho Biotech, Roche, Shire, Trimeris, and ViroLogic; he has received honoraria from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Roche, and ViroLogic and grant support from Abbott, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Roche, and Tanox; Dr Pillay has served as a consultant to, and has received research grants from

GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Roche, and Tibotec-Virco; Dr Richman has served as a consultant to Abbott, Achillion, Bristol-Myers Squibb, Chiron, Gilead, GlaxoSmithKline, Merck, Novirio, Pfizer, Roche, Tibotec-Virco, Triangle, and ViroLogic; Dr Schapiro has served as a scientific advisor to Roche and Visible Genetics and on the speakers bureau for Abbott, Bristol-Myers Squibb, and Roche; he has received other financial support from GlaxoSmithKline and Virology Education; Dr Telenti has no affiliations to disclose.

Top HIV Med. 2003;11(6):215-221

Copyright © 2003 International AIDS Society–USA
